Bayer AG - Company Snapshot & SWOT Analysis
Bayer is a German multinational pharmaceutical and life sciences company with a more than 150-year history and core competencies in the areas of health care and agriculture, is one of the largest pharmaceutical companies in the world.
Company’s innovative products are contributing to finding solutions to some of the major challenges of recent time. Bayer's main goal is to create value for their customers, stockholders and employees, while also strengthening the company’s financials.
Revenues at the Pharmaceuticals segment increased 1.8% to €4,291 million in the fourth quarter. Growth was backed by consistent strong performance of key products like Xarelto, Eylea, Xofigo, Stivarga and Adempas. Strongest sales growth among the other top Pharmaceuticals products was recorded for the diabetes treatment Glucobay, driven by expanded volumes in China.
Bayer's core earnings came down to USD 1.75 per share in 2018 compared with earnings of USD 1.87 in 2017. Earnings have beaten the Zacks Consensus Estimate of USD1.63.
Bayer's revenue in 2018 stands at €39.58 Billion, up from €35.01 billion in 2017.
Spanning over 35 pages and 17 exhibits, “Bayer AG - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for Bayer AG.
Scope of the Bayer AG - Company Snapshot & SWOT Analysis Report
This report provides detailed information about Bayer AG including value chain analysis, financial performance, business strategy and SWOT analysis.
The report identifies the growth drivers and inhibitors for global pharmaceutical market.
This report provides information about current and future trends for global pharmaceutical market.
Company’s innovative products are contributing to finding solutions to some of the major challenges of recent time. Bayer's main goal is to create value for their customers, stockholders and employees, while also strengthening the company’s financials.
Revenues at the Pharmaceuticals segment increased 1.8% to €4,291 million in the fourth quarter. Growth was backed by consistent strong performance of key products like Xarelto, Eylea, Xofigo, Stivarga and Adempas. Strongest sales growth among the other top Pharmaceuticals products was recorded for the diabetes treatment Glucobay, driven by expanded volumes in China.
Bayer's core earnings came down to USD 1.75 per share in 2018 compared with earnings of USD 1.87 in 2017. Earnings have beaten the Zacks Consensus Estimate of USD1.63.
Bayer's revenue in 2018 stands at €39.58 Billion, up from €35.01 billion in 2017.
Spanning over 35 pages and 17 exhibits, “Bayer AG - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for Bayer AG.
Scope of the Bayer AG - Company Snapshot & SWOT Analysis Report
This report provides detailed information about Bayer AG including value chain analysis, financial performance, business strategy and SWOT analysis.
The report identifies the growth drivers and inhibitors for global pharmaceutical market.
This report provides information about current and future trends for global pharmaceutical market.
1. EXECUTIVE SUMMARY
Scope of the Bayer AG - Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1. Bayer AG Company Profile
3.1.1. Company Profile
3.1.2 Bayer in Global Pharmaceuticals Manufacturing Value Chain
3.1.3 Bayer: Financial Performance
3.1.3.1 Bayer: Overall Revenue FY 2013-FY 2019 (in Euro billion)
3.1.3.2 Bayer: Division-Wise Revenue FY 2018 (in Euro billion)
3.1.3.3 Bayer: Geography-Wise Revenue FY 2018 (in Euro billion)
3.1.3.4 Bayer: Best Selling Pharmaceutical Products Revenue FY 2018 (in Euro billion)
3.1.3.5 Bayer: Best Selling Consumer Health Products Revenue FY 2018 (in Euro billion)
3.1.3.6 Bayer: Crop Science Segment-Wise Revenue FY 2018 (in Euro billion)
3.1.3.7 Bayer: Best Selling Animal Health Products Revenue FY 2018 (in Euro billion)
3.1.4 Bayer AG: Business Strategy
3.1.4.1 Product Level Strategy
3.1.5 SWOT Analysis of Bayer AG
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Notes
Company Information
Scope of the Bayer AG - Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1. Bayer AG Company Profile
3.1.1. Company Profile
3.1.2 Bayer in Global Pharmaceuticals Manufacturing Value Chain
3.1.3 Bayer: Financial Performance
3.1.3.1 Bayer: Overall Revenue FY 2013-FY 2019 (in Euro billion)
3.1.3.2 Bayer: Division-Wise Revenue FY 2018 (in Euro billion)
3.1.3.3 Bayer: Geography-Wise Revenue FY 2018 (in Euro billion)
3.1.3.4 Bayer: Best Selling Pharmaceutical Products Revenue FY 2018 (in Euro billion)
3.1.3.5 Bayer: Best Selling Consumer Health Products Revenue FY 2018 (in Euro billion)
3.1.3.6 Bayer: Crop Science Segment-Wise Revenue FY 2018 (in Euro billion)
3.1.3.7 Bayer: Best Selling Animal Health Products Revenue FY 2018 (in Euro billion)
3.1.4 Bayer AG: Business Strategy
3.1.4.1 Product Level Strategy
3.1.5 SWOT Analysis of Bayer AG
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Notes
Company Information
LIST OF EXHIBITS
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Bayer
Exhibit 3.2 Contact Information of Bayer
Exhibit 3.3 Division-Wise Revenue of Bayer in FY 2018 (in Euro billion)
Exhibit 3.4 Pharmaceuticals Division Revenue of Bayer FY 2013- FY 2018 (in Euro billion)
Exhibit 3.5 Consumer Health Division Revenue of Bayer FY 2013- FY 2018 (in Euro billion)
Exhibit 3.6 Crop Science Division Revenue of Bayer FY 2013- FY 2018 (in Euro billion)
Exhibit 3.7 Animal Health Division Revenue of Bayer FY 2013- FY 2018 (in Euro billion)
Exhibit 3.8 Geography-Wise Revenue of Bayer in FY 2018 (in Euro billion)
Exhibit 3.9 Best Selling Pharmaceuticals Product Revenue of Bayer FY 2018 (in Euro billion)
Exhibit 3.10 Best Selling Consumer Health Product Revenue of Bayer FY 2018 (in Euro billion)
Exhibit 3.11 Crop Science Segment-Wise Revenue of Bayer FY 2018 (in Euro billion)
Exhibit 3.12 Best Selling Animal Health Product Revenue of Bayer FY 2018 (in Euro billion)
Exhibit 3.13 Bayer's Research and Development Projects (Phase II) as of January 31, 2019
Exhibit 3.14 Bayer's Research and Development Projects (Phase III) as of January 31, 2019
Exhibit 3.15 Bayer's Main Products Submitted for Approval as of January 31, 2019
Exhibit 3.16 SWOT Analysis of Bayer AG
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Bayer
Exhibit 3.2 Contact Information of Bayer
Exhibit 3.3 Division-Wise Revenue of Bayer in FY 2018 (in Euro billion)
Exhibit 3.4 Pharmaceuticals Division Revenue of Bayer FY 2013- FY 2018 (in Euro billion)
Exhibit 3.5 Consumer Health Division Revenue of Bayer FY 2013- FY 2018 (in Euro billion)
Exhibit 3.6 Crop Science Division Revenue of Bayer FY 2013- FY 2018 (in Euro billion)
Exhibit 3.7 Animal Health Division Revenue of Bayer FY 2013- FY 2018 (in Euro billion)
Exhibit 3.8 Geography-Wise Revenue of Bayer in FY 2018 (in Euro billion)
Exhibit 3.9 Best Selling Pharmaceuticals Product Revenue of Bayer FY 2018 (in Euro billion)
Exhibit 3.10 Best Selling Consumer Health Product Revenue of Bayer FY 2018 (in Euro billion)
Exhibit 3.11 Crop Science Segment-Wise Revenue of Bayer FY 2018 (in Euro billion)
Exhibit 3.12 Best Selling Animal Health Product Revenue of Bayer FY 2018 (in Euro billion)
Exhibit 3.13 Bayer's Research and Development Projects (Phase II) as of January 31, 2019
Exhibit 3.14 Bayer's Research and Development Projects (Phase III) as of January 31, 2019
Exhibit 3.15 Bayer's Main Products Submitted for Approval as of January 31, 2019
Exhibit 3.16 SWOT Analysis of Bayer AG
